Pure Global
NCT06136962

Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life

A Comprehensive Prospective Study on the 10-Year Outcome and Late Toxicity, Quality of Life of Reduced Volume Intensity Modulated Radiation Therapy in Nasopharyngeal Carcinoma
Fujian Cancer Hospital·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Nasopharyngeal Carcinoma
Study type
Observational
Sponsor & location
Primary sponsor
Fujian Cancer Hospital
Location
Fuzhou, China
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2023
End date
Dec 01, 2024
Enrollment
500 participants
Primary outcome

Overall survival

Summary

Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer. The last three decades of
 research in head and neck radiation oncology have largely focused on improvements in
 survival, which have mostly come at the cost of long term toxicity for surviving
 patients.This is an observational study that is being done to evaluate the long-term
 efficacy, learn about the toxicity and quality of life that survivors of nasopharyngeal
 carcinoma may have following treated with reduced volume intensity modulated radiation
 therapy.

ICD-10 classifications
Malignant neoplasm of nasopharynxMalignant neoplasm: Nasopharynx, unspecifiedMalignant neoplasm: Overlapping lesion of nasopharynxBenign neoplasm: NasopharynxMalignant neoplasm: Posterior wall of nasopharynx
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06136962
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06136962 through Pure Global AI's free database. This phase not specified trial is sponsored by Fujian Cancer Hospital and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.